Florida Clinical Research Center

Maitland, Florida 34208

0 studies enrolling now · 13 studies all time

What they study most

ADHD, Attention Deficit Disorder With Hyperactivity, Attention Deficit Hyperactivity Disorder (ADHD), Attention-Deficit/Hyperactivity Disorder, Major Depressive Disorder, Opioid Dependence, Opioid Related Disorders, Opioid Use Disorder, Opioid-related Disorders, Schizoaffective Disorder, Schizophrenia, Schizophreniform Disorder

Studies at this site

• A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) — Completed
• Open-label Long Term (52 Weeks) Safety and Tolerability of Agomelatine Sublingual Tablets in Major Depressive Disorder (MDD) — Stopped early
• Software Treatment for Actively Reducing Severity of ADHD — Completed
• The Efficacy and Safety of PRC-063 in Adult ADHD Patients — Completed
• Software Treatment for Actively Reducing Severity of ADHD - Follow Up — Completed
• Long Term Study of RBP 7000 in the Treatment of Subjects With Schizophrenia — Completed
• Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder — Completed
• Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine — Completed
• NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD) — Completed
• A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment. — Completed
• A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs) — Completed
• Study of Safety & Tolerability of OPC-34712 as Adjunctive Therapy in Treatment of Adult Patients With Major Depressive Disorder — Completed
• Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects — Stopped early